BioCentury | Dec 21, 2019
Company News

Dec. 20 Company Quick Takes: Genmab partners with CureVac; plus pair of Biogen deals, Ionis, Akcea-Novartis, Paratek and J&J-Taris

...cancer Johnson & Johnson (NYSE:JNJ) acquired bladder disease company Taris Biomedical LLC. Taris’ lead candidate, TAR-200...
BioCentury | Dec 22, 2017
Financial News

Drug delivery company Taris raises $25M series B

...said it partnered with BMS to conduct a Phase Ib trial of Taris' lead program TAR-200...
...in patients who are scheduled for radical cystectomy. The companies did not disclose financial terms. TAR-200...
...$32 million in a series A round in 2015. Taris Biomedical LLC, Lexington, Mass. Jaime De Leon gemcitabine-releasing intravesical system nivolumab Opdivo TAR-200 Bristol-Myers...
BioCentury | Dec 21, 2017
Financial News

Taris raises $25M series B

...said it partnered with BMS to conduct a Phase Ib trial of Taris' lead program TAR-200...
...in patients who are scheduled for radical cystectomy. The companies did not disclose financial terms. TAR-200...
...in a series A round in 2015 (see BioCentury Extra, Oct. 27, 2015) . Jaime De Leon gemcitabine-releasing intravesical system GemRIS nivolumab Opdivo TAR-200 Bristol-Myers...
BioCentury | Jan 6, 2017
Clinical News

TAR-200: Preliminary Ph Ib data

...patients with muscle invasive bladder cancer in an open-label, U.S. Phase Ib trial showed that TAR-200...
...cystectomy. TAR-200 was well tolerated. Taris Biomedical LLC , Lexington, Mass. Product: GemRIS , gemcitabine-releasing intravesical system (TAR-200...
...immunohistochemical tumor analysis of biomarkers Status: Preliminary Phase Ib data Milestone: Start Phase II (2017) Julian Zhu gemcitabine-releasing intravesical system GemRIS TAR-200 Taris...
BioCentury | Aug 15, 2016
Clinical News

GemRIS: Phase Ib started

...Taris began an open-label, European Phase Ib trial to evaluate TAR-200 inserted into the bladder for...
...Ib testing for MIBC. Taris Biomedical LLC , Lexington, Mass. Product: GemRIS , gemcitabine-releasing intravesical system ( TAR-200...
BioCentury | Jul 25, 2016
Clinical News

GemRIS: Phase Ib started

...Taris began an open-label, U.S. Phase Ib trial to evaluate TAR-200 inserted into the bladder for...
...patients before radical cystectomy. Taris Biomedical LLC , Lexington, Mass. Product: GemRIS , gemcitabine-releasing intravesical system ( TAR-200...
BioCentury | Oct 28, 2015
Financial News

Taris Biomedical raises $32M series A

...CMO Christopher Searcy said the company expects to begin clinical studies next year of both TAR-200...
Items per page:
1 - 7 of 7